In a promising advancement for Parkinson’s disease research, scientists at the Federal University of São Paulo (UNIFESP) have uncovered a novel neuroprotective approach that may shift the paradigm of how this debilitating neurodegenerative disorder is treated. Detailed in a recent publication in the journal Neuropharmacology, their groundbreaking study explores the therapeutic potential of a peptide fragment derived from Annexin A1, named Ac2-26, which exhibits remarkable anti-inflammatory effects in a mouse model of Parkinson’s disease.
Parkinson’s disease, a progressive disorder characterized predominantly by the death of dopaminergic neurons in the substantia nigra, leads to a debilitating reduction in dopamine levels. This neurotransmitter is crucial for regulating motor control, motivation, and reward, and its deficiency manifests as hallmark symptoms such as tremors, rigidity, and bradykinesia. Traditionally, treatments have focused mainly on symptomatic relief through dopamine replacement therapies, notably levodopa, which, despite its efficacy in early stages, encounters diminishing returns due to long-term complications.
The UNIFESP researchers have shifted the focus toward the underlying neuroinflammatory processes that exacerbate neuronal death. Annexin A1, a protein intrinsically involved in resolving inflammation, has been shown to be altered in Parkinsonian brains, signifying its potential role in disease progression. Their innovative approach leverages the Ac2-26 peptide, an N-terminal fragment of Annexin A1, known for its potent anti-inflammatory properties. Previous animal studies had suggested the peptide’s capacity to modulate neuroinflammation, but UNIFESP’s investigation is among the first to elucidate its precise effects on dopaminergic neuron preservation in Parkinson’s models.
In their experiments, the team employed a neurotoxin, 6-hydroxydopamine (6-OHDA), to entrench a Parkinson-like state in mice by inducing selective dopaminergic neuron degeneration. Simultaneously administering Ac2-26 intraperitoneally, they observed a significant preservation of these critical neurons, as confirmed via immunofluorescence imaging which highlighted the dopaminergic neurons’ survival post-treatment. This neuroprotection appears to stem from the peptide’s ability to mitigate the inflammatory microenvironment within the brain, an environment often hostile to neuronal longevity in Parkinson’s disease.
What makes this research particularly compelling is the study’s emphasis on neuroinflammation as a target distinct from dopamine replacement. According to Cristiane Damas Gil, the lead investigator and head of the Department of Morphology and Genetics at UNIFESP’s São Paulo School of Medicine, targeting the inflammatory cascade offers a strategy to preserve neuronal architecture and function prior to irreversible degeneration. This contrasts with levodopa’s approach which primarily substitutes dopamine without addressing inflammatory mediators that drive ongoing neuronal damage.
Furthermore, the research highlights intriguing sex differences in disease progression. Female mice initially demonstrated greater resilience against neurodegeneration and better motor performance following 6-OHDA administration, a phenomenon observed even in genetically modified mice lacking Annexin A1. This points to complex biological factors underpinning Parkinson’s pathology and underscores the necessity for sex-specific therapeutic regimens, especially given that the peptide’s protective mechanisms may interface differently with male and female physiology.
Beyond neuroprotection, the study uncovered an unsettling impact of Parkinson’s-like injury on female reproductive cycles, shedding light on the neuroendocrine disruptions associated with Parkinson’s disease. Such findings suggest that the disease’s reach extends beyond motor symptoms, influencing systemic physiological processes, thereby prompting calls for more comprehensive clinical evaluation and tailored treatment interventions.
Luiz Philipe de Souza Ferreira, the principal researcher supported by a FAPESP scholarship, stresses the need for alternative interventions. While levodopa remains the clinical standard due to its symptomatic benefits, it often loses efficacy over time and can engender motor complications like dyskinesias. Therefore, therapies like Ac2-26 that intervene early in the disease’s pathogenesis by curbing inflammation could complement or eventually supplant dopamine-based treatments.
The Ac2-26 peptide has established anti-inflammatory roles in other disease contexts but has yet to progress to clinical pharmaceutical development. Its application in Parkinson’s models constitutes a frontier for translational neuroscience. This peptide’s intervention at the nascent phase of neuronal injury opens the possibility for disease-modifying therapies that could slow or halt the relentless progression currently characteristic of Parkinson’s.
Looking toward the future, the research team is keen to investigate whether Ac2-26’s benefits extend beyond prevention to actively reversing existing neuronal damage. Achieving such a breakthrough could dramatically alter the therapeutic landscape, transforming Parkinson’s from an inevitably progressive disease to a manageable chronic condition, or potentially one with regenerative treatment options.
The implications of this work extend across the fields of neuropharmacology, neurobiology, and clinical neurology. It paves a pathway toward nuanced targeting of neuroinflammation, which has been increasingly recognized as a critical axis in neurodegeneration. Leveraging endogenous proteins and their fragments that naturally orchestrate inflammatory resolution could herald a new class of neuroprotective agents with high specificity and minimal side effects.
These findings, supported by the São Paulo Research Foundation (FAPESP), reflect the burgeoning capacity of Brazilian science to contribute significantly to global neurodegenerative disease research. As the field intensifies its search for mechanistic-based therapies, molecules like Ac2-26 offer tangible hope for patients suffering from Parkinson’s disease, potentially reshaping the future of treatment and improving quality of life for millions worldwide.
Subject of Research: Parkinson’s disease neurodegeneration and neuroinflammation targeting through the Ac2-26 peptide derived from Annexin A1.
Article Title: Annexin A1 and its N-terminal peptide Ac2-26 regulate dopaminergic degeneration and neuroinflammation in a 6-OHDA model of Parkinson’s disease
News Publication Date: 23-Mar-2026
Web References:
https://sciencedirect.com/science/article/pii/S0028390826001152
References:
Ferreira, L.P. de S., Gil, C.D., et al. (2026). Annexin A1 and its N-terminal peptide Ac2-26 regulate dopaminergic degeneration and neuroinflammation in a 6-OHDA model of Parkinson’s disease. Neuropharmacology. DOI: 10.1016/j.neuropharm.2026.110942
Image Credits: Luiz Philipe de Souza Ferreira et al./Neuropharmacology
Keywords
Parkinson’s disease, neuroinflammation, dopaminergic neurons, Ac2-26 peptide, Annexin A1, neuroprotection, 6-OHDA model, levodopa alternatives, neurodegenerative diseases, sex differences in Parkinson’s, endogenous anti-inflammatory agents, neuropharmacology
Tags: Ac2-26 therapeutic potentialAnnexin A1 peptide Ac2-26Annexin A1 role in neurodegenerationanti-inflammatory therapy for Parkinson’sdopamine deficiency motor symptomsdopaminergic neuron preservationFederal University of São Paulo Parkinson’s studymouse model Parkinson’s researchneuroinflammation in Parkinson’snovel Parkinson’s disease treatmentsParkinson’s disease neuroprotectionpeptide-based neurodegenerative treatment
